MedTrace Logo

Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)

NCT02329769 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2017-12-08

No results posted yet for this study

Summary

The purpose of this study is to see whether PRO044 is safe and effective to use as medication for Duchenne Muscular Dystrophy (DMD) patients with a mutation around location 44 in the DNA for the dystrophin protein.

Conditions

Interventions

DRUG

PRO044 SC 6 mg/kg

DRUG

PRO044 IV 6 mg/kg

DRUG

PRO044 IV 9 mg/kg

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
9 Years
Max Age
20 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-07-01
Completion
2016-08-31

Countries

  • Belgium
  • Italy
  • Netherlands
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02329769 on ClinicalTrials.gov